Synchroneuron, LLC
Lexington, MA, US· latest recorded location
Synchroneuron, LLC is named on 15 US grants and 14 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 15
- Published applications
- 14
- Inventors
- 7
- Granted in 2026 so far
- 0
- Most recent grant
- 24 Dec 2019
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 2 | 0 |
| 2000 | 3 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 2 |
| 2003 | 0 | 0 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 1 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 4 |
| 2014 | 0 | 0 |
| 2015 | 0 | 2 |
| 2016 | 3 | 2 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 2 | 0 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 1 |
By publication year.
Technology areas
Share of 29 documents
Recent patents
- Methods of treating posttraumatic stress disorder with acamprosate salts24 Dec 2019US 10,512,621 B2
- Acamprosate formulations, methods of using the same, and combinations comprising the same1 Jan 2019US 10,166,207 B2
- Acamprosate formulations, methods of using the same, and combinations comprising the same30 Aug 2016US 9,427,420 B2
- Acamprosate formulations, methods of using the same, and combinations comprising the same23 Aug 2016US 9,421,178 B2
- Acamprosate formulations, methods of using the same, and combinations comprising the same23 Aug 2016US 9,421,179 B2
- Formulations16 Jun 2022US 2022/0184007 A1
- Acamprosate formulations, methods of using the same, and combinations comprising the same27 Feb 2020US 2020/0061003 A1
- Acamprosate formulations, methods of using the same, and combinations comprising the same16 Feb 2017US 2017/0042839 A1
- Acamprosate formulations, methods of using the same, and combinations comprising the same14 Apr 2016US 2016/0101075 A1
- Acamprosate formulations, methods of using the same, and combinations comprising the same24 Mar 2016US 2016/0081938 A1
Most cited
By later US patents
- Methods of treating tardive dyskinesia and other movement disorders72US 5,952,389 A1999
- Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists48US 6,057,373 A2000
- Methods of treating tardive dyskinesia and other movement disorders43US 6,294,583 B12001
- Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders40US 6,689,816 B22004
- Methods of treating tardive dyskinesia using NMDA receptor antagonists38US 5,866,585 A1999